HELSINKI, Feb 6 (Reuters) - Finnish drugs group Orion (ORNBV.HE: Quote, Profile , Research) said it is considering contributing to a possible additional study on heart failure drug Simdax, and that it could carry about 20 million euros ($25.9 million) of the costs.
